Samuel Dara

473 total citations
10 papers, 313 citations indexed

About

Samuel Dara is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Samuel Dara has authored 10 papers receiving a total of 313 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Genetics and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Samuel Dara's work include Acute Lymphoblastic Leukemia research (7 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Samuel Dara is often cited by papers focused on Acute Lymphoblastic Leukemia research (7 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Samuel Dara collaborates with scholars based in United States. Samuel Dara's co-authors include Farhad Ravandi, Hagop M. Kantarjian, Susan O’Brien, Gautam Borthakur, Stefan Faderl, Guillermo Garcia‐Manero, Jörge E. Cortes, Dan Jones, Rebecca Garris and Partow Kebriaei and has published in prestigious journals such as Blood, British Journal of Haematology and HemaSphere.

In The Last Decade

Samuel Dara

10 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel Dara United States 5 256 255 75 67 57 10 313
Sherry Pierce United States 4 222 0.9× 262 1.0× 58 0.8× 72 1.1× 38 0.7× 5 342
Seo Ej South Korea 5 153 0.6× 277 1.1× 68 0.9× 52 0.8× 14 0.2× 5 297
Manuela Tosi Italy 6 209 0.8× 204 0.8× 42 0.6× 54 0.8× 48 0.8× 12 236
C. Knechtli United Kingdom 8 340 1.3× 355 1.4× 36 0.5× 69 1.0× 92 1.6× 9 425
Laura Kingsbury United States 6 143 0.6× 161 0.6× 30 0.4× 86 1.3× 26 0.5× 8 219
Giovanni Reddiconto Italy 7 172 0.7× 85 0.3× 30 0.4× 38 0.6× 90 1.6× 9 291
Joie Alvarez United States 2 136 0.5× 122 0.5× 36 0.5× 64 1.0× 26 0.5× 2 163
Kirsten Bleckmann Germany 9 140 0.5× 120 0.5× 18 0.2× 34 0.5× 39 0.7× 12 192
Aurélie Boeree Netherlands 7 207 0.8× 182 0.7× 34 0.5× 28 0.4× 81 1.4× 18 253
Mayur Parihar India 9 93 0.4× 111 0.4× 43 0.6× 51 0.8× 36 0.6× 44 196

Countries citing papers authored by Samuel Dara

Since Specialization
Citations

This map shows the geographic impact of Samuel Dara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Dara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Dara more than expected).

Fields of papers citing papers by Samuel Dara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Dara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Dara. The network helps show where Samuel Dara may publish in the future.

Co-authorship network of co-authors of Samuel Dara

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Dara. A scholar is included among the top collaborators of Samuel Dara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Dara. Samuel Dara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Senapati, Jayastu, Jo Ishizawa, Hussein A. Abbas, et al.. (2022). P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA. HemaSphere. 6. 475–476. 2 indexed citations
2.
Cortes, Jörge E., Hagop M. Kantarjian, Guillaume Richard‐Carpentier, et al.. (2019). Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood. 134(Supplement_1). 2941–2941. 1 indexed citations
3.
Benton, Christopher B., Deborah A. Thomas, Hui Yang, et al.. (2014). Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology. 167(3). 356–365. 33 indexed citations
4.
Ravandi, Farhad, Susan O’Brien, Deborah Thomas, et al.. (2010). First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. Blood. 116(12). 2070–2077. 244 indexed citations
5.
6.
Garcia‐Manero, Guillermo, Deborah A. Thomas, Michael Rytting, et al.. (2009). A Phase 1 Study of Dose-Dense 5-Aza-2′-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).. Blood. 114(22). 2030–2030. 3 indexed citations
7.
8.
9.
Ravandi, Farhad, Deborah Thomas, Hagop Kantarjian, et al.. (2008). Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood. 112(11). 2921–2921. 5 indexed citations
10.
Faderl, Stefan, Deborah A. Thomas, Charles Koller, et al.. (2008). Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL). Blood. 112(11). 3960–3960. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherry Pierce Breakdown of academic impact, for papers by Seo Ej Breakdown of academic impact, for papers by Manuela Tosi Breakdown of academic impact, for papers by C. Knechtli Breakdown of academic impact, for papers by Laura Kingsbury Breakdown of academic impact, for papers by Giovanni Reddiconto Breakdown of academic impact, for papers by Joie Alvarez Breakdown of academic impact, for papers by Kirsten Bleckmann Breakdown of academic impact, for papers by Aurélie Boeree Breakdown of academic impact, for papers by Mayur Parihar
Rankless by CCL
2026